Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM313 in Platelet Transfusion Refractoriness
NCT06792019Phase 2Recruiting
- Sponsor
- Keymed Biosciences
- Start
- Mar 2025
- Primary completion
- Nov 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cm313 in platelet transfusion refractoriness (PTR) (2 arms), sponsored by Keymed Biosciences. Primary endpoint: Adverse events (AE) at 24 weeks. Started Mar 2025; status: recruiting.
02
Drugs
cm313
03
Conditions
platelet transfusion refractoriness (PTR)
Beyond the preview
Go deeper on NCT06792019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06792019.